1. Home
  2. VAL vs CRSP Comparison

VAL vs CRSP Comparison

Compare VAL & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Valaris Limited

VAL

Valaris Limited

HOLD

Current Price

$82.07

Market Cap

5.9B

Sector

Energy

ML Signal

HOLD

CRSP

CRISPR Therapeutics AG

BUY

Current Price

$54.11

Market Cap

5.8B

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
VAL
CRSP
Founded
1975
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
5.8B
IPO Year
2021
2016

Fundamental Metrics

Financial Performance
Metric
VAL
CRSP
Price
$82.07
$54.11
Analyst Decision
Hold
Buy
Analyst Count
9
22
Target Price
$67.43
★ $87.56
AVG Volume (30 Days)
1.2M
★ 1.4M
Earning Date
10-28-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 170.70
N/A
EPS
★ 0.48
N/A
Revenue
★ $2,369,000,000.00
$289,590,000.00
Revenue This Year
N/A
$1,063.30
Revenue Next Year
$13.43
$283.48
P/E Ratio
$173.94
★ N/A
Revenue Growth
0.27
★ 9169.85
52 Week Low
$46.85
$44.12
52 Week High
$114.12
$78.48

Technical Indicators

Market Signals
Indicator
VAL
CRSP
Relative Strength Index (RSI) 49.17 46.68
Support Level $81.99 $51.81
Resistance Level $92.19 $60.52
Average True Range (ATR) 2.88 3.32
MACD -0.14 -0.08
Stochastic Oscillator 45.98 25.75

Price Performance

Historical Comparison
VAL
CRSP

About VAL Valaris Limited

Valaris Ltd is an offshore contract drilling company. The company provides offshore contract drilling services to the international oil and gas industry with operations in almost every offshore market across six continents. Its business consists of four operating segments: Floaters, which includes drillships and semisubmersible rigs; Jackups; ARO; and Other, which consists of management services on rigs owned by third parties. It generates the majority of its revenue from the Floaters segment.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: